Despite the implication in the report, Pfizer never validated Theranos’s technology, he said, and came to the opposite conclusion. Holmes sent the report to Walgreens and others. Weber said Theranos and Pfizer had no meaningful business after 2010, the period when Ms. Balwani were “much more relaxed” and “social” outside working hours, but “nothing in particular” stood out about their dynamic, Mr. Balwani’s romantic relationship, which they kept secret. “Generally, she was the C.E.O., so she had the final decision-making authority,” he said.īecause of his friendship with Ms.
#MARKED KEY TRIAL#
Balwani, who faces a separate trial next year, has denied these allegations. Holmes’s lawyers have indicated in filings that they may argue Mr. Holmes, the government will have to prove that she - and not Sunny Balwani, Theranos’s former chief operating officer and her former boyfriend - was the one calling the shots. Prosecutors said that was still misleading, since the line said Theranos’s use of venous draws was “uncommon.” Earlier testimony showed that Theranos used venous draws in about 40 percent of its tests for Walgreens. In a November 2013 email, she wrote that a line acknowledging that Theranos used venous draws - the typical method of blood testing that Theranos had promised to disrupt by using a single drop of blood - should be moved from a footnote to the main text. Holmes’s lawyer pointed out instances when she encouraged transparency in Theranos’s marketing language. Holmes had been “very involved and detail oriented” in reviewing and approving all marketing and investor materials. An example was language claiming that Theranos’s machines could run “any test available in central labs” using blood only “1/1,000 the size of a typical blood draw.”īut similar language made it to investor presentations, documents showed. In emails shown to jurors, the start-up’s lawyer, Kate Beardsley, marked draft website copy as potentially misleading. Other questions concerned Theranos’s marketing. Edlin said a Theranos executive had instructed him to remove some results before sending Mr. Murdoch’s test results came back with various issues.
Any blood results?”Īccording to an email sent to Mr. Murdoch had his blood drawn in a demonstration in January 2015. In some cases, he said, Theranos also removed abnormal results before sending out reports to investors who had tested the company’s technology, such as Rupert Murdoch, the media mogul. Edlin testified that Theranos sometimes hid failures or didn’t even try to analyze a blood sample during technology demonstrations. Holmes’s brother who became a senior product manager at Theranos. This week’s star witness was Daniel Edlin, a college friend of Ms. Here are the key takeaways from the week’s proceedings. Holmes faces 12 counts of wire fraud and conspiracy to commit wire fraud. Holmes’s alleged deceptions, trying to make the case that she intentionally misled Theranos’s investors, commercial partners and the United States military. In previous weeks, jurors heard from former Theranos lab employees who detailed the blood-testing technology and retail partners who testified about how the start-up had failed to hit deadlines or achieve agreed-upon goals. In the seventh week of the fraud trial of Elizabeth Holmes, the founder of the failed blood-testing start-up Theranos, testimony moved away from science and into discussions of faked demonstrations and misleading marketing.
0 kommentar(er)
